Services
Research
Training
Industry
About us
ChEBI
Examples:
iron*
,
InChI=1S/CH4O/c1-2/h2H,1H3
,
caffeine
Advanced
Home
Advanced Search
Browse
Documentation
Download
Tools
About ChEBI
Submit
Contact us
DiNA
Statistics
Entity of the Month
Periodic Table
Ontology
Train online
User Manual
Annotation Manual
Developer Manual
FAQ's
BiNChE
libChEBI
Web Services
ChEBI
> Main
CHEBI:71217 - pazopanib hydrochloride
Main
ChEBI Ontology
Automatic Xrefs
Reactions
Pathways
Models
ChEBI Name
pazopanib hydrochloride
ChEBI ID
CHEBI:71217
Definition
A hydrochloride salt prepared from equimolar amounts of pazopanib and hydrochloric acid. Used for treatment of kidney cancer.
Stars
This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download
Molfile
XML
SDF
Find compounds which contain this structure
Find compounds which resemble this structure
Take structure to the Advanced Search
more structures >>
Molfile
Molfile
Wikipedia
License
Read full article at Wikipedia
Formula
C21H24ClN7O2S
Net Charge
0
Average Mass
473.97900
Monoisotopic Mass
473.14007
InChI
InChI=1S/C21H23N7O2S.ClH/c1-
13-
5-
6-
15(11-
19(13)
31(22,29)
30)
24-
21-
23-
10-
9-
20(25-
21)
27(3)
16-
7-
8-
17-
14(2)
28(4)
26-
18(17)
12-
16;/h5-
12H,1-
4H3,(H2,22,29,30)
(H,23,24,25)
;1H
InChIKey
MQHIQUBXFFAOMK-UHFFFAOYSA-N
SMILES
Cl.C1=C(C(=CC(=C1)NC=2N=CC=C(N2)N(C=3C=CC=4C(C3)=NN(C4C)C)C)S(N)(=O)=O)C
Roles Classification
Biological Role
(s):
vascular endothelial growth factor receptor antagonist
An antagonist at the vascular endothelial growth factor receptor.
tyrosine kinase inhibitor
Any protein kinase inhibitor that interferes with the action of tyrosine kinase.
Application
(s):
angiogenesis modulating agent
An agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents.
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing
pazopanib hydrochloride (
CHEBI:71217
)
has part
pazopanib(1+) (
CHEBI:71218
)
pazopanib hydrochloride (
CHEBI:71217
)
has role
angiogenesis modulating agent (
CHEBI:50926
)
pazopanib hydrochloride (
CHEBI:71217
)
has role
antineoplastic agent (
CHEBI:35610
)
pazopanib hydrochloride (
CHEBI:71217
)
has role
tyrosine kinase inhibitor (
CHEBI:38637
)
pazopanib hydrochloride (
CHEBI:71217
)
has role
vascular endothelial growth factor receptor antagonist (
CHEBI:65207
)
pazopanib hydrochloride (
CHEBI:71217
)
is a
hydrochloride (
CHEBI:36807
)
IUPAC Name
5-
({4-
[(2,3-
dimethyl-
2
H
-
indazol-
6-
yl)(methyl)amino]pyrimidin-
2-
yl}amino)-
2-
methylbenzenesulfonamide hydrochloride
Synonyms
Sources
5-
((4-
((2,3-
Dimethyl-
2H-
indazol-
6-
yl)methylamino)pyrimidin-
2-
yl)amino)-
2-
methylbenzenesulfonamide monohydrochloride
ChemIDplus
GW786034B
ChemIDplus
pazopanib HCl
ChEBI
pazopanib monohydrochloride
ChEBI
Brand Name
Source
Votrient
KEGG DRUG
Manual Xrefs
Databases
D05380
KEGG DRUG
Pazopanib_hydrochloride
Wikipedia
US2008293691
Patent
WO2005105094
Patent
WO2006020564
Patent
WO2007064753
Patent
WO2007143483
Patent
WO2009062658
Patent
WO2011069053
Patent
WO2011150044
Patent
View more database links
Registry Numbers
Types
Sources
11572612
Reaxys Registry Number
Reaxys
635702-64-6
CAS Registry Number
ChemIDplus
635702-64-6
CAS Registry Number
KEGG DRUG
Citations
Types
Sources
18040531
PubMed citation
Europe PMC
19229381
PubMed citation
Europe PMC
19365030
PubMed citation
Europe PMC
19427156
PubMed citation
Europe PMC
19798455
PubMed citation
Europe PMC
19954277
PubMed citation
Europe PMC
19967103
PubMed citation
Europe PMC
20043026
PubMed citation
Europe PMC
20189340
PubMed citation
Europe PMC
20383346
PubMed citation
Europe PMC
20407031
PubMed citation
Europe PMC
20664824
PubMed citation
Europe PMC
21225019
PubMed citation
Europe PMC
21470066
PubMed citation
Europe PMC
21995103
PubMed citation
Europe PMC
22074946
PubMed citation
Europe PMC
22341567
PubMed citation
Europe PMC
22679111
PubMed citation
Europe PMC
22984765
PubMed citation
Europe PMC
Last Modified
03 February 2020